Insight Molecular Company Insiders
| IMDX Stock | 6.62 0.10 1.53% |
Insight Molecular employs about 46 people. The company is managed by 11 executives with a total tenure of roughly 108 years, averaging almost 9.0 years of service per executive, having 4.18 employees per reported executive. Break down of Insight Molecular's management performance can provide insight into the company performance.
Insight Molecular's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Insight Molecular's future performance. Based on our forecasts, it is anticipated that Insight will maintain a workforce of slightly above 50 employees by March 2026.Insight Molecular Management Team Effectiveness
The company has return on total asset (ROA) of (0.2217) % which means that it has lost $0.2217 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.2896) %, meaning that it created substantial loss on money invested by shareholders. Insight Molecular's management efficiency ratios could be used to measure how well Insight Molecular manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 4.67 in 2026, despite the fact that Return On Tangible Assets are likely to grow to (3.24). At this time, Insight Molecular's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 32.8 M in 2026, whereas Other Current Assets are likely to drop slightly above 1.1 M in 2026.Common Stock Shares Outstanding is likely to rise to about 15.8 M in 2026Insight Molecular Diagnostics has a total of 28.6 Million outstanding shares. Over half of Insight Molecular's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 32 M | Current Value 32 M | Avarage Shares Outstanding 5.9 M | Quarterly Volatility 7.5 M |
Insight Molecular Workforce Comparison
Insight Molecular Diagnostics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,071. Insight Molecular holds roughly 46.0 in number of employees claiming about 4% of equities under Health Care industry.
Insight Molecular Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insight Molecular insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insight Molecular's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Insight Molecular insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 9.0 | 9 | 1 | 2,877,288 | 0.00 |
| 2023-12-01 | 0.5 | 1 | 2 | 8,482 | 277,987 |
| 2023-06-01 | 6.0 | 18 | 3 | 31,180,306 | 6,650,363 |
| 2023-03-01 | 1.6667 | 5 | 3 | 802,823 | 8,221,186 |
| 2022-12-01 | 0.4286 | 6 | 14 | 863,797 | 1,647,710 |
| 2022-09-01 | 21.0 | 21 | 1 | 1,263,000 | 1,176 |
| 2022-06-01 | 3.4545 | 38 | 11 | 30,480,576 | 327,531 |
| 2021-09-01 | 0.8 | 4 | 5 | 638,461 | 137,834 |
| 2021-06-01 | 3.4 | 17 | 5 | 630,207 | 181,714 |
| 2020-12-01 | 4.25 | 17 | 4 | 331,915 | 43,700 |
| 2020-06-01 | 10.0 | 10 | 1 | 1,528,221 | 20,000 |
| 2020-03-01 | 3.5 | 14 | 4 | 2,386,898 | 2,660,006 |
| 2019-09-01 | 3.5 | 14 | 4 | 3,270,000 | 6,570,000 |
| 2018-09-01 | 19.0 | 19 | 1 | 504,476 | 250,000 |
| 2018-06-01 | 7.0 | 7 | 1 | 725,000 | 20,000 |
| 2017-09-01 | 2.0 | 2 | 1 | 0.00 | 0.00 |
| 2017-03-01 | 5.0 | 5 | 1 | 306,900 | 0.00 |
| 2016-12-01 | 0.5 | 1 | 2 | 230,769 | 150,000 |
| 2016-09-01 | 0.6667 | 2 | 3 | 40,000 | 1,538,462 |
Insight Molecular Notable Stakeholders
An Insight Molecular stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Insight Molecular often face trade-offs trying to please all of them. Insight Molecular's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Insight Molecular's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Joshua Riggs | CEO President | Profile | |
| Michael West | CoCEO Advisor | Profile | |
| Peter Hong | General VP | Profile | |
| Gabrielle Woody | Executive Assistant | Profile | |
| Andrea James | Chief Officer | Profile | |
| James Liu | Treasurer, Accounting | Profile | |
| Ekkehard MD | Chief Officer | Profile | |
| YuhMin Chiang | Chief Officer | Profile | |
| FACP MD | Consulting Officer | Profile | |
| MD FACP | Consulting Officer | Profile | |
| Sandra ODonald | Senior Operations | Profile |
About Insight Molecular Management Performance
The success or failure of an entity such as Insight Molecular often depends on how effective the management is. Insight Molecular management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Insight management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Insight management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.41) | (3.24) | |
| Return On Capital Employed | (2.52) | (2.40) | |
| Return On Assets | (1.99) | (1.89) | |
| Return On Equity | 4.45 | 4.67 |
Please note, the imprecision that can be found in Insight Molecular's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Insight Molecular Diagnostics. Check Insight Molecular's Beneish M Score to see the likelihood of Insight Molecular's management manipulating its earnings.
Insight Molecular Workforce Analysis
Traditionally, organizations such as Insight Molecular use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Insight Molecular within its industry.Insight Molecular Manpower Efficiency
Return on Insight Molecular Manpower
| Revenue Per Employee | 40.9K | |
| Revenue Per Executive | 171K | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 5.5M | |
| Working Capital Per Employee | 97.5K | |
| Working Capital Per Executive | 407.6K |
Additional Tools for Insight Stock Analysis
When running Insight Molecular's price analysis, check to measure Insight Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insight Molecular is operating at the current time. Most of Insight Molecular's value examination focuses on studying past and present price action to predict the probability of Insight Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insight Molecular's price. Additionally, you may evaluate how the addition of Insight Molecular to your portfolios can decrease your overall portfolio volatility.